BIGFATE O

BIGFATE O is a dual-component gastrointestinal mucosal protectant combining sucralfate — a cytoprotective mucosal adherent — with oxetacaine — a topical anaesthetic — providing both healing and immediate symptomatic relief for acid-related mucosal injury.

Sucralfate (1gm per 5mL) is a sulfated disaccharide-aluminium hydroxide complex with a unique, non-systemic mechanism of action. In the acid environment of the stomach (pH below 4), sucralfate undergoes polymerisation into a viscous, sticky gel that preferentially binds to exposed proteins at ulcer crater surfaces — forming a physical protective barrier that shields the mucosa from further acid, pepsin, and bile injury. The binding affinity of sucralfate for damaged epithelium is 6 times higher than for normal epithelium, explaining its selective localisation to ulcer sites.

Beyond physical barrier formation, sucralfate has multiple active cytoprotective effects: it stimulates local prostaglandin E2 synthesis (promoting mucosal defence mechanisms), binds and inactivates bile salts and pepsin, promotes bicarbonate secretion from the mucosa, and enhances epidermal growth factor binding to mucosal cells — all contributing to accelerated ulcer healing. Sucralfate is minimally absorbed (less than 3–5% systemically), exerting its full therapeutic effect locally in the GI lumen without systemic pharmacological activity.

Oxetacaine (20mg per 5mL) is a topical local anaesthetic of the amide class that rapidly blocks sodium channels in sensory nerve endings in the oropharyngeal and oesophageal/gastric mucosa. By stabilising the neuronal membrane and preventing action potential propagation, oxetacaine provides immediate, dose-dependent anaesthesia of the inflamed mucosal surface — directly relieving the burning, stinging, and retrosternal discomfort of oesophagitis, gastritis, and peptic ulceration within minutes of administration. The combination of immediate anaesthetic relief (oxetacaine) with sustained mucosal healing (sucralfate) addresses both the acute symptom and the underlying mucosal injury simultaneously.

BIGFATE O is indicated for acid-related conditions involving mucosal inflammation, injury, or ulceration where both local anaesthetic symptom relief and mucosal protection/healing are required.

Peptic Ulcer Disease: Gastric and duodenal ulcers — sucralfate promotes ulcer healing by protecting the crater base and stimulating mucosal defence. Particularly valuable as adjunct therapy with PPIs where rapid symptom control is needed during the initial healing phase.

Gastro-Oesophageal Reflux Disease (GORD) and Reflux Oesophagitis: Sucralfate adheres to the lower oesophageal mucosa, protecting against acid reflux injury. Oxetacaine provides immediate relief of retrosternal burning — faster than PPIs which require 2–4 days to achieve full acid suppression.

Gastritis: Acute and chronic gastritis — BIGFATE O provides both mucosal protection and symptomatic relief from epigastric pain and burning.

Post-Surgical GI Protection: Oesophageal, gastric, and duodenal surgery — sucralfate's mucosal adherence protects anastomotic sites and raw mucosal surfaces from acid injury during healing.

ENT Indications: Laryngopharyngeal reflux (LPR) and post-ENT surgical oropharyngeal mucosal injury — oxetacaine provides local anaesthesia for pain management while sucralfate protects exposed pharyngeal surfaces.

Stress Ulcer Prophylaxis: Prevention of stress ulcers in critically ill or post-operative patients where acid suppression alone may be insufficient.

Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.